Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 7Leiomyoma 5Triple Negative Breast Neoplasms 3Prostatic Neoplasms 2Breast Neoplasms, Male 2Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2 1Neoplasms 1Gulf War Illness 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Female 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Mifepristone × Clear all
NCT03225547 2025-12-23

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

University of Chicago

Phase 2 Terminated
24 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

University of Chicago

Phase 2 Active not recruiting
29 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05062174 2022-12-15

Breast Cancer BRCA1 Carriers: a Pilot Study

Indiana University

Withdrawn
Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡